474 related articles for article (PubMed ID: 24239580)
21. Enhanced oral bioavailability of paclitaxel by D-alpha-tocopheryl polyethylene glycol 400 succinate in mice.
Ho PY; Yeh TK; Yao HT; Lin HL; Wu HY; Lo YK; Chang YW; Chiang TH; Wu SH; Chao YS; Chen CT
Int J Pharm; 2008 Jul; 359(1-2):174-81. PubMed ID: 18513900
[TBL] [Abstract][Full Text] [Related]
22. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo.
Varma MV; Panchagnula R
Eur J Pharm Sci; 2005; 25(4-5):445-53. PubMed ID: 15890503
[TBL] [Abstract][Full Text] [Related]
23. Oral delivery of paclitaxel nanocrystal (PNC) with a dual Pgp-CYP3A4 inhibitor: preparation, characterization and antitumor activity.
Patel K; Patil A; Mehta M; Gota V; Vavia P
Int J Pharm; 2014 Sep; 472(1-2):214-23. PubMed ID: 24954663
[TBL] [Abstract][Full Text] [Related]
24. P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.
Kimura Y; Aoki J; Kohno M; Ooka H; Tsuruo T; Nakanishi O
Cancer Chemother Pharmacol; 2002 Apr; 49(4):322-8. PubMed ID: 11914912
[TBL] [Abstract][Full Text] [Related]
25. Vitamin E loaded resveratrol nanoemulsion for brain targeting for the treatment of Parkinson's disease by reducing oxidative stress.
Pangeni R; Sharma S; Mustafa G; Ali J; Baboota S
Nanotechnology; 2014 Dec; 25(48):485102. PubMed ID: 25392203
[TBL] [Abstract][Full Text] [Related]
26. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel.
Moes J; Koolen S; Huitema A; Schellens J; Beijnen J; Nuijen B
Eur J Pharm Biopharm; 2013 Jan; 83(1):87-94. PubMed ID: 23085332
[TBL] [Abstract][Full Text] [Related]
27. Nanoemulsion-based delivery system for enhanced oral bioavailability and caco-2 cell monolayers permeability of berberine hydrochloride.
Li YJ; Hu XB; Lu XL; Liao DH; Tang TT; Wu JY; Xiang DX
Drug Deliv; 2017 Nov; 24(1):1868-1873. PubMed ID: 29191058
[TBL] [Abstract][Full Text] [Related]
28. Curcumin enhances oral bioavailability and anti-tumor therapeutic efficacy of paclitaxel upon administration in nanoemulsion formulation.
Ganta S; Devalapally H; Amiji M
J Pharm Sci; 2010 Nov; 99(11):4630-41. PubMed ID: 20845461
[TBL] [Abstract][Full Text] [Related]
29. A TPGS-incorporating nanoemulsion of paclitaxel circumvents drug resistance in breast cancer.
Bu H; He X; Zhang Z; Yin Q; Yu H; Li Y
Int J Pharm; 2014 Aug; 471(1-2):206-13. PubMed ID: 24866272
[TBL] [Abstract][Full Text] [Related]
30. Optimization of nutraceutical coenzyme Q10 nanoemulsion with improved skin permeability and anti-wrinkle efficiency.
El-Leithy ES; Makky AM; Khattab AM; Hussein DG
Drug Dev Ind Pharm; 2018 Feb; 44(2):316-328. PubMed ID: 29096550
[TBL] [Abstract][Full Text] [Related]
31. Transdermal delivery of anticancer drug caffeine from water-in-oil nanoemulsions.
Shakeel F; Ramadan W
Colloids Surf B Biointerfaces; 2010 Jan; 75(1):356-62. PubMed ID: 19783127
[TBL] [Abstract][Full Text] [Related]
32. Effects of silymarin and formulation on the oral bioavailability of paclitaxel in rats.
Park JH; Park JH; Hur HJ; Woo JS; Lee HJ
Eur J Pharm Sci; 2012 Feb; 45(3):296-301. PubMed ID: 22172604
[TBL] [Abstract][Full Text] [Related]
33. Nebulized oil-in-water nanoemulsion mists for pulmonary delivery: development, physico-chemical characterization and in vitro evaluation.
Nesamony J; Shah IS; Kalra A; Jung R
Drug Dev Ind Pharm; 2014 Sep; 40(9):1253-63. PubMed ID: 23837519
[TBL] [Abstract][Full Text] [Related]
34. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability.
Patel N; Nakrani H; Raval M; Sheth N
Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408
[TBL] [Abstract][Full Text] [Related]
35. Wheat germ agglutinin-conjugated PLGA nanoparticles for enhanced intracellular delivery of paclitaxel to colon cancer cells.
Wang C; Ho PC; Lim LY
Int J Pharm; 2010 Nov; 400(1-2):201-10. PubMed ID: 20804835
[TBL] [Abstract][Full Text] [Related]
36. Development of stabilized Paclitaxel nanocrystals: In-vitro and in-vivo efficacy studies.
Sharma S; Verma A; Teja BV; Shukla P; Mishra PR
Eur J Pharm Sci; 2015 Mar; 69():51-60. PubMed ID: 25559064
[TBL] [Abstract][Full Text] [Related]
37. Self-emulsifying O/W formulations of paclitaxel prepared from mixed nonionic surfactants.
Lo JT; Chen BH; Lee TM; Han J; Li JL
J Pharm Sci; 2010 May; 99(5):2320-32. PubMed ID: 19894274
[TBL] [Abstract][Full Text] [Related]
38. Folate-mediated solid-liquid lipid nanoparticles for paclitaxel-coated poly(ethylene glycol).
Wu L; Tang C; Yin C
Drug Dev Ind Pharm; 2010 Apr; 36(4):439-48. PubMed ID: 19824865
[TBL] [Abstract][Full Text] [Related]
39. Preparation and evaluation of a water-in-oil nanoemulsion drug delivery system loaded with salidroside.
Liang CX; Qi DL; Zhang LN; Lu P; Liu ZD
Chin J Nat Med; 2021 Mar; 19(3):231-240. PubMed ID: 33781457
[TBL] [Abstract][Full Text] [Related]
40. Cremophor-free intravenous microemulsions for paclitaxel I: formulation, cytotoxicity and hemolysis.
Nornoo AO; Osborne DW; Chow DS
Int J Pharm; 2008 Feb; 349(1-2):108-16. PubMed ID: 17869459
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
